B Brux
Overview
Explore the profile of B Brux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, et al.
Urol Res
. 2003 Sep;
31(6):358-62.
PMID: 14513300
The M2 isoenzyme of pyruvate kinase (M2-PK) is specifically expressed in tumor cells (TuM2-PK) and has been detected in the peripheral blood of patients with renal cell carcinoma (RCC). TuM2-PK...
2.
Jung K, Lein M, von Hosslin K, Brux B, Schnorr D, Loening S, et al.
Clin Chem
. 2001 Oct;
47(11):2061-3.
PMID: 11673385
No abstract available.
3.
Jung K, Stephan C, Elgeti U, Lein M, Brux B, Kristiansen G, et al.
Int J Cancer
. 2001 Jul;
93(5):759-65.
PMID: 11477592
Molecular forms of prostate-specific antigen (PSA) improve the differentiation between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) in men with total PSA concentrations between 4 and 10 microg/l. To...
4.
Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, et al.
Prostate
. 2001 May;
47(2):77-84.
PMID: 11340629
Background: The aim was to evaluate the clinical performance of alpha(1)-antichymotrypsin prostate-specific antigen (PSA-ACT) for early diagnosis of prostate cancer (PCa) in a multicenter trial. Methods: Three hundred sixty-seven white...
5.
Lein M, Jung K, Elgeti U, Brux B, Sinha P, Schnorr D, et al.
Anticancer Res
. 2001 May;
20(6D):4997-5001.
PMID: 11326657
Objective: To evaluate the analytical performance and diagnostic utility of prostate specific antigen (PSA) bound to alpha 1-antichymotrypsin (ACT) in serum to improve the differentiation between benign prostatic hyperplasia (BPH)...
6.
Jung K, Stephan C, Lein M, Brux B, Sinha P, Schnorr D, et al.
Prostate
. 2001 Mar;
46(4):307-10.
PMID: 11241553
Background: Receiver-operating characteristic (ROC) analysis is often applied as evaluation tool to compare the diagnostic validity of laboratory tests. The aim of this study was to draw attention to preconditions...
7.
Jung K, Lein M, Brux B, Sinha P, Schnorr D, Loening S
Clin Chem Lab Med
. 2001 Feb;
38(12):1271-5.
PMID: 11205692
The effect of sample collection, storage conditions (time and temperature), and freeze-thaw cycles on the stability of free prostate-specific antigen (fPSA), PSA complexed with alpha1-antichymotrypsin (ACT-PSA), and total PSA (tPSA)...
8.
Lein M, Jung K, Elgeti U, Petras T, Stephan C, Brux B, et al.
Eur Urol
. 2001 Feb;
39(1):57-64.
PMID: 11173940
Objective: To evaluate the diagnostic utility of free prostate specific antigen (fPSA), alpha-1- antichymotrypsin-bound PSA (PSA-ACT), complexed PSA (cPSA), and including their associated ratios to total PSA (tPSA) in serum...
9.
Stephan C, Jung K, Brux B, Lein M, Sinha P, Schnorr D, et al.
Clin Chem Lab Med
. 2000 Aug;
38(4):309-11.
PMID: 10928650
Total prostate-specific antigen (PSA) and complexed PSA were determined in venous blood from 12 patients with prostate cancer before and after radical prostatectomy by using Immuno 1 PSA assays. The...
10.
Stephan C, Jung K, Brux B, Lein M, Sinha P, Schnorr D, et al.
Urology
. 2000 Mar;
55(4):560-3.
PMID: 10736503
Objectives: To study the elimination kinetics of alpha(1)-antichymotrypsin (ACT)-prostate-specific antigen (PSA) and complexed PSA (cPSA) in comparison to the biexponential decrease of total PSA and free PSA after radical prostatectomy....